Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointments of Michael Chambers and Kathryn Boor, Ph.D., to its Board of Directors. Both Mr. Chambers and Dr. Boor bring distinct and invaluable experience to the Sarepta board that will help guide the company on its mission to change the course of life-threatening rare diseases.

“We’re pleased to welcome two new board members whose participation will contribute to the realization of Sarepta’s strategic vision to create transformative therapies for patients with rare diseases,” said M. Kathleen Behrens, Ph.D., Chairperson of Sarepta’s Board of Directors.

“Mr. Chambers’ appointment brings tremendous bioscience and entrepreneurial leadership, along with deep expertise in areas of fundamental importance to genetic medicine innovators. Dr. Boor, in addition to her scientific and academic credentials, is an expert in environment, sustainability and governance, a topic of significant importance to Sarepta,” said Doug Ingram, Sarepta’s president and chief executive officer. “These new appointments add to the diversity of experience and perspective on our Board, providing outstanding leadership as we work with the greatest urgency to bring innovative genetic medicines to patients.”

Mr. Chambers co-founded Aldevron, based in Fargo, N.D., in 1998, and served as its chief executive officer for more than 20 years before serving as Executive Chairman of the Board until 2021 when Aldevron was acquired for $9.6 billion. As founder, Chambers oversaw the growth of Aldevron into a world-class service organization, specializing in nucleic acid and protein production, antibody development, and custom services with operations in the United States and Europe. Chambers currently serves on the Board of Directors at Calviri, Inc.

In 2018, Chambers was named one of the “100 Most Intriguing Entrepreneurs” by Goldman Sachs.  He earned his bachelor’s degree in biotechnology, microbiology, and chemistry from North Dakota State University.  

Dr. Boor is the Dean of the Graduate School and Vice Provost for Graduate Education at Cornell University. Previously, Dr. Boor served as the Ronald P. Lynch Dean of the College of Agriculture and Life Sciences (CALS) at Cornell.  She earned a bachelor’s degree in food science from Cornell University, a master’s degree in food science from the University of Wisconsin and a Ph.D. in microbiology from the University of California, Davis. She joined the Cornell Food Science department as assistant professor in 1994, became its first tenured female faculty member in 2000, and led as department chair from 2007-2010.

Dr. Boor serves on the Board of Directors for Seneca Foods Corporation, International Flavors and Fragrances, the United States-Israel Binational Agricultural Research and Development (BARD) Fund, and the Foundation for Food and Agriculture Research (FFAR). She serves on the Science Board for the US Food and Drug Administration and on the New York State Southern Tier Regional Economic Development Council. 

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements related to Sarepta’s mission to change the course of life-threatening rare diseases and the potential benefits of the additions of Dr. Boor and Michael Chambers to Sarepta’s Board.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Known risk factors include, among others: Sarepta may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, clinical development plans, and bringing its products to U.S. and ex-U.S. markets for various reasons including possible limitations of Company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, and regulatory, court or agency decisions, such as decisions by the United States Patent and Trademark Office with respect to patents that cover Sarepta’s product candidates; and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual Report on Form 10-K for the year ended December 31, 2021, and most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com